BlueCrest Capital Management’s Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A BSX.PRA Stock Holding History

BlueCrest Capital Management’s Portfolio BSX.PRA Stock Details BSX.PRA Fund Activity

Upgrade to unlock

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell
2023 Q1	$10.2M	Buy
2022 Q4	$7.92M	Buy
2022 Q3	$1.32M	Buy
2022 Q2	–	Sell
2022 Q1	$3.88M	Sell
2021 Q4	$4.05M	Buy
2020 Q3	–	Sell
2020 Q2	$2.59M	Buy